Currently, drugs are developed with advanced knowledge about drug-disease interactions to the molecular level. Newer categories called precision medicines are often associated with receptor-ligand “lock and key” mechanisms of action. Despite advances in science and technology, all drugs including precision medicine solutions are administered in the same way as they were 70-plus years ago, yet they have a > 90% failure rate during development.
At Cytonus, we challenge the status quo because we find this failure rate to be unacceptable. We believe precision medicine solutions are only as good as how they’re administered, and all future drug candidates that don’t account for the complexities of the human body won’t move the needle towards better outcomes.
To make next-generation drugs, a pragmatic shift is needed to make drug candidates that are both functional (efficacious) and safe simultaneously.